Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.82 | — | — | — | — | 26.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 16.01 | 379.47 | 7.40 | 19.02 | 8.65 | 2.98 | 33.05 | 2.51 | 81.08 | 79.27 | 130.30 | 133.45 | 411.99 | 369.84 | 4784.42 | 3218.45 | 2690.83 | 1987.76 | 2106.24 | 10475.97 | 7623.85 |
| — | +12643.3% | -77.6% | +656.8% | -89.3% | -96.2% | -74.6% | -98.1% | -80.3% | -78.6% | -97.3% | -95.9% | -84.7% | -81.4% | +127.2% | -69.3% | -64.7% | +180.6% | -73.0% | +1892.7% | +119413.6% | |
| P/B Ratio | 6.06 | 6.02 | 3.08 | 3.89 | 4.08 | 2.66 | 1.36 | 1.83 | 3.18 | 2.18 | 2.04 | 4.02 | 1.91 | 2.52 | 5.22 | 3.08 | 2.91 | 3.93 | 3.36 | 5.16 | 5.13 |
| — | +126.6% | +127.0% | +112.5% | +28.4% | +22.1% | -33.5% | -54.6% | +66.1% | -13.5% | -60.9% | +30.8% | -34.3% | -36.0% | +55.1% | -40.4% | -43.2% | -18.7% | -39.0% | +93.0% | +165.8% | |
| P/FCF | — | — | — | — | — | 5.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 24.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 294.33 | — | — | 17.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.4% | 94.4% | 99.5% | 94.2% | 99.9% | 99.3% | 97.6% | 2.3% | 95.9% | 89.9% | 84.5% | -2012.8% | 95.7% | 97.5% | 100.0% | -267.9% | 100.0% | 100.0% | -194.6% | -117742.9% | 100.0% |
| — | -4.9% | +1.9% | +3927.7% | +4.2% | +10.4% | +15.5% | +100.1% | +0.3% | -7.8% | -15.5% | -651.5% | -4.3% | -2.5% | +151.4% | +99.8% | 0.0% | +102.3% | +99.6% | -29447.1% | +10.5% | |
| Operating Margin | -98.2% | -3835.3% | -4.7% | -269.1% | -85.9% | 12.9% | -2034.8% | -123.3% | -3639.6% | -3360.9% | -4011.8% | -6657.7% | -30636.4% | -13955.8% | -129758.3% | -108135.7% | -59217.9% | -68591.4% | -63189.2% | -180928.6% | -99834.8% |
| — | -29732.8% | +99.8% | -118.3% | +97.6% | +100.4% | +49.3% | +98.1% | +88.1% | +75.9% | +96.9% | +93.8% | +48.3% | +79.7% | -105.3% | +40.2% | +40.7% | -793.7% | +18.1% | -4727.7% | -7741.2% | |
| Net Margin | -101.1% | -4591.8% | -4.9% | -282.7% | -90.0% | 11.3% | -2004.4% | -127.2% | -3703.5% | -3244.0% | -4282.9% | -7087.7% | -31188.3% | -14165.3% | -133058.3% | -108907.1% | -59966.7% | -70248.6% | -63448.6% | -182935.7% | -100530.4% |
| — | -40858.4% | +99.8% | -122.3% | +97.6% | +100.3% | +53.2% | +98.2% | +88.1% | +77.1% | +96.8% | +93.5% | +48.0% | +79.8% | -109.7% | +40.5% | +40.3% | -809.8% | +18.3% | -6525.0% | -8173.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.7% | -16.8% | -0.7% | -13.6% | -10.2% | 2.6% | -18.8% | -20.8% | -31.0% | -20.2% | -25.3% | -42.8% | -31.0% | -32.7% | -31.1% | -23.4% | -21.8% | -30.1% | -22.8% | -20.5% | -16.9% |
| — | -753.7% | +96.4% | +34.5% | +67.0% | +112.7% | +25.8% | +51.3% | +0.1% | +38.3% | +18.6% | -83.2% | -42.4% | -8.8% | -36.8% | -14.1% | -28.9% | -141.2% | -67.7% | -354.6% | -107.9% | |
| ROA | -20.8% | -12.2% | -0.5% | -7.9% | -5.9% | 1.2% | -8.5% | -10.9% | -18.7% | -13.5% | -15.0% | -19.7% | -17.0% | -18.7% | -17.9% | -15.8% | -15.4% | -19.8% | -17.2% | -16.6% | -13.4% |
| — | -1085.3% | +94.6% | +27.1% | +68.3% | +109.2% | +43.3% | +44.6% | -9.6% | +27.8% | +16.3% | -24.5% | -10.7% | +5.3% | -4.0% | +4.6% | -14.5% | -99.8% | -62.9% | -476.8% | -140.8% | |
| ROIC | -22.7% | -11.2% | -0.4% | -8.2% | -6.0% | 1.7% | -10.9% | -11.2% | -17.1% | -13.6% | -14.3% | -17.5% | -18.0% | -21.6% | -19.2% | -16.1% | -15.0% | -27.0% | -31.7% | -34.4% | -29.0% |
| — | -770.2% | +96.2% | +27.1% | +64.9% | +112.2% | +24.0% | +35.8% | +5.1% | +36.8% | +25.4% | -8.5% | -19.7% | +19.9% | +39.6% | +53.1% | +48.2% | -27.8% | -12.2% | -204.9% | -145.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.58 | — | 0.28 | 0.58 | 0.54 | 0.47 | 0.86 | 0.74 | 0.59 | 0.44 | 0.37 | 1.14 | 0.76 | 0.57 | 0.63 | 0.47 | 0.21 | 0.36 | 0.28 | 0.02 | 0.10 |
| — | — | -67.1% | -22.1% | -8.9% | +7.8% | +134.8% | -34.8% | -21.9% | -22.2% | -41.7% | +141.3% | +257.3% | +57.8% | +129.4% | +2253.1% | +104.6% | +287.8% | +231.0% | -75.5% | -56.4% | |
| Debt / EBITDA | — | — | — | — | — | 15.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.88 | 13.37 | 18.79 | 4.88 | 5.64 | 4.16 | 2.22 | 5.44 | 7.45 | 11.51 | 15.58 | 5.60 | 6.92 | 10.10 | 5.38 | 6.08 | 7.54 | 3.85 | 4.68 | 4.02 | 3.62 |
| — | +221.0% | +746.4% | -10.3% | -24.3% | -63.8% | -85.8% | -2.8% | +7.6% | +13.9% | +189.8% | -7.9% | -8.2% | +162.4% | +15.0% | +51.3% | +108.2% | +2.5% | +25.4% | +19.3% | +134.4% | |
| Quick Ratio | 4.87 | 13.29 | 18.77 | 4.87 | 5.63 | 4.16 | 2.22 | 5.44 | 7.43 | 11.49 | 15.56 | 5.58 | 6.91 | 10.09 | 5.38 | 6.08 | 7.54 | 3.85 | 4.68 | 4.02 | 3.62 |
| — | +219.4% | +745.8% | -10.4% | -24.2% | -63.8% | -85.7% | -2.7% | +7.5% | +13.8% | +189.4% | -8.1% | -8.3% | +162.3% | +15.0% | +51.3% | +108.2% | +2.5% | +25.4% | +19.3% | +134.4% | |
| Interest Coverage | -5.04 | -11.18 | 0.34 | -6.65 | -4.93 | 2.40 | -12.78 | -5.30 | -13.21 | -23.17 | -9.01 | -8.36 | -11.96 | -21.91 | -16.54 | -26.65 | -26.07 | -33.97 | -212.42 | -85.86 | -134.22 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LXRX stock.
Lexicon Pharmaceuticals, Inc.'s current P/E is -12.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Lexicon Pharmaceuticals, Inc.'s current operating margin is -98.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Lexicon Pharmaceuticals, Inc.'s business trajectory between earnings reports.